Newron Overcomes 2011 Disappointments, Moves To Boost CNS Pipeline With NeuroNova Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Italy's Newron aims to become a leading European CNS-focused biotech company with the proposed acquisition of Sweden's NeuroNova adding product candidates in ALS and Parkinson's disease to its portfolio.
You may also be interested in...
Germany's Merck Returns Safinamide To Newron, Merger With Biotie Now Under Review
The surprise announcement by Merck Serono to return all rights to safinamide to Italy's Newron has led to Biotie Therapies and Newron reviewing their plans to merge.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.